West Pharmaceutical Services (WST) Common Equity (2009 - 2026)

West Pharmaceutical Services' Common Equity history runs 18 years deep, the most recent figure standing at $3.0 billion for Q1 2026.

• In Q1 2026, Common Equity rose 11.45% year-over-year to $3.0 billion; the TTM figure through Mar 2026 stood at $3.0 billion (up 11.45% YoY), while the FY2025 annual figure was $3.2 billion, up 18.41% from the prior year.
• Common Equity came in at $3.0 billion for Q1 2026 at West Pharmaceutical Services, down from $3.2 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $3.2 billion in Q4 2025 to a low of $2.3 billion in Q1 2022.
• A 5-year average of $2.7 billion and a median of $2.7 billion in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity climbed 27.18% in 2022 and fell 6.9% in 2024, its largest moves.
• West Pharmaceutical Services' Common Equity stood at $2.7 billion in 2022, then grew by 7.3% to $2.9 billion in 2023, then fell by 6.9% to $2.7 billion in 2024, then gained by 18.41% to $3.2 billion in 2025, then fell by 5.84% to $3.0 billion in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $3.0 billion, $3.2 billion, and $3.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison